Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Permissive Versus Strict Intrapartum Glucose Management in Type 1 Diabetes (PRISM-T1D)

NCT: NCT07293715 · RECRUITING

NCT IDNCT07293715
StatusRECRUITING
Start Date2026-02-25
Completion2027-06

Brief Summary

PRISM-TID is a single center non-inferiority randomized controlled trial of permissive intrapartum glucose management (intervention) versus strict intrapartum glucose management (standard of care) among pregnant individuals with type 1 diabetes (T1D) using hybrid closed loop therapy (HCL) who are admitted for labor management. Participants will be randomized in a 1:1 fashion to one of two intrapartum glycemic control options: permissive (70-140 mg/dL) or strict (70-110 mg/dL). The primary aim of this trial it to demonstrate that permissive intrapartum glucose management is not associated with an increased risk of neonatal dysglycemia compared with strict intrapartum glucose management.

Frequently Asked Questions

What is Permissive Versus Strict Intrapartum Glucose Management in Type 1 Diabetes (PRISM-T1D)?

Permissive Versus Strict Intrapartum Glucose Management in Type 1 Diabetes (PRISM-T1D) is a clinical trial registered under NCT07293715. Current status: RECRUITING.

What is the status of NCT07293715?

The current status of NCT07293715 (Permissive Versus Strict Intrapartum Glucose Management in Type 1 Diabetes (PRISM-T1D)) is: RECRUITING.

When did Permissive Versus Strict Intrapartum Glucose Management in Type 1 Diabetes (PRISM-T1D) start?

Permissive Versus Strict Intrapartum Glucose Management in Type 1 Diabetes (PRISM-T1D) started on 2026-02-25.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.